Clinic Director, Clinical Genetics Service
I am a board-certified medical oncologist who specializes in the identification and management of individuals who have inherited an increased risk for cancer. As Clinic Director of the Clinical Genetics Service, I concentrate on helping men and women with cancer incorporate genetic information into their treatment plan. For those who are at increased risk, but have not been diagnosed, I work to develop a plan that will help them either prevent the development of cancer, or limit its impact if it occurs. Along the same lines, my research focus has studied the best ways to use genetic information to improve the outcomes of those with or at risk for hereditary cancers of all types.
Consistent with the goals I pursue in my clinical genetics work, my oncology practice is weighted toward the management of young women with breast cancer, especially hereditary breast cancer. As part of that practice, I participate in the development of new treatments, such as PARP inhibitors, which may be particularly useful for this group of women. Finally, I also maintain a separate practice where I coordinate screening for women with mutations in BRCA1 or BRCA2.
- Clinical Expertise: General Hematology/Oncology; Breast Cancer; Genetic Predisposition to Cancer; Cancer Risk Counseling
- Languages Spoken: English
- Education: MD, University of Virginia School of Medicine
- Residencies: Walter Reed Army Medical Center
- Fellowships: Walter Reed Army Medical Center
- Board Certifications: Internal Medicine; Medical Oncology; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Mark E. Robson
- A Phase II Study of BMN 673 (Talazoparib) in Patients with Locally Advanced or Metastatic Breast Cancer Containing a BRCA Mutation
- A Phase III Study of Olaparib versus Standard Chemotherapy to Treat Patients with Metastatic Breast Cancer Who Have BRCA Mutations
- Understanding Decision-Making Processes for Undergoing Genetic Testing Among Women with Newly Diagnosed Breast Cancer